COVID-19
The changes are unlikely to help people in developing countries but could reduce innovation among biopharma companies and ultimately do more harm than good.
New research from the Allen Institute for Immunology in Seattle has identified inflammatory proteins as a potential driver of the long COVID.
Since the COVID-19 pandemic, there has been increased interest in developing a universal antiviral that would stop a pandemic in its tracks. Now some companies are in the testing phase for just that.
On Thursday at the White House, President Biden paid tribute to the 1 million American lives lost due to COVID-19.
Jacqueline Shea will take over as the new CEO and announced plans to discontinue its Phase III Innovate trial to prioritize its heterologous booster strategy for COVID-19.
ICER recommended two out of three outpatient treatments for COVID-19 in today’s market, singling out molnupiravir as having inadequate evidence that it is better than symptomatic care.
Current COVID-19 booster shots have a problem: they last only about four months and appear to have limited efficacy in a vaccinated population. Clearly, a more durable approach is needed.
Despite posting its first profitable quarter as a commercial stage company, shares of Novavax plunged 20% in Tuesday trading due to the slower-than-expected rollout of its COVID-19 vaccine.
Moderna is still fending off patent challenges over the lipid nanoparticle delivery system used in its COVID-19 vaccine.
Life Science industries are seeing massive financial fluctuations in how they’re handling the COVID-19 pandemic, but there is some optimism of a recovery by biopharma executives.
PRESS RELEASES